Back to search results

Study to Assess Stopping Prostate Cancer Treatment Early in Elderly Patients

This study is looking at whether it's possible to safely stop LHRH agonist therapy (a type of hormone treatment) in older men (70 years or older) who have prostate cancer and have been on this treatment for a long time (more than 3 years). The researchers believe that these patients might not need to continue the therapy. If you join, your testosterone and PSA levels will be checked regularly for up to 3 years after stopping the LHRH agonist therapy. The main goal is to see if stopping this treatment is practical and safe for patients like you. This study is currently unclear about its recruitment status.

Study design
This study plans to enroll 155 elderly men with prostate cancer. It is an interventional study, meaning participants will receive a specific intervention (discontinuing LHRH agonist therapy).
What's involved
Participants will discontinue LHRH agonist therapy and have their testosterone and PSA levels monitored for up to 3 years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for up to 3 years after discontinuing LHRH agonist therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06824818

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

Recruiting
NAAges 70+InterventionalTreatment
University of Chicago
~155 participants
Updated 2025-10-01 on ClinicalTrials.gov
What's tested:LHRH Agonist Therapy Discontinuation

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
feasibility of stopping LHRH agonist therapy
Measured over 12 months after discontinuing LHRH agonist therapy

Conditions

Elderly
Prostate Cancer

Explore related trials

Prostate CarcinomaTestosterone

Where it's being run

2 sites across 1 states
Illinois2

Study leadership

  • Nabiel Mir, MD · STUDY_CHAIR · University of Chicago

Who to contact

Clinical Trials Intake
[email protected]
1-855-702-8222
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Prostate cancer with \>3 years of LHRH agonist therapy.
Age ≥70 years.
ECOG performance status ≤2
Baseline testosterone of \< 20 ng/ml
No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable).
Ability to understand and sign informed consent.

Exclusion

none

What this trial measures

  • feasibility of stopping LHRH agonist therapy12 months after discontinuing LHRH agonist therapy

    Fraction of patients maintaining castrate testosterone levels